Spuch Carlos, Navarro Carmen
Department of Pathology and Neuropathology, University Hospital of Vigo (CHUVI), Hospital of Meixoeiro, Meixoeiro s/n, 36215 Vigo, Spain.
J Drug Deliv. 2011;2011:469679. doi: 10.1155/2011/469679. Epub 2011 Dec 13.
Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease represent a huge unmet medical need. The prevalence of both diseases is increasing, but the efficacy of treatment is still very limited due to various factors including the blood brain barrier (BBB). Drug delivery to the brain remains the major challenge for the treatment of all neurodegenerative diseases because of the numerous protective barriers surrounding the central nervous system. New therapeutic drugs that cross the BBB are critically needed for treatment of many brain diseases. One of the significant factors on neurotherapeutics is the constraint of the blood brain barrier and the drug release kinetics that cause peripheral serious side effects. Contrary to common belief, neurodegenerative and neurological diseases may be multisystemic in nature, and this presents numerous difficulties for their potential treatment. Overall, the aim of this paper is to summarize the last findings and news related to liposome technology in the treatment of neurodegenerative diseases and demonstrate the potential of this technology for the development of novel therapeutics and the possible applications of liposomes in the two most widespread neurodegenerative diseases, Alzheimer's disease and Parkinson's disease.
神经退行性疾病，如阿尔茨海默病和帕金森病，代表着巨大的未被满足的医疗需求。这两种疾病的患病率都在上升，但由于包括血脑屏障（BBB）在内的各种因素，治疗效果仍然非常有限。由于中枢神经系统周围存在众多保护屏障，将药物输送到大脑仍然是所有神经退行性疾病治疗的主要挑战。治疗许多脑部疾病急需能够穿过血脑屏障的新型治疗药物。神经治疗学的一个重要因素是血脑屏障的限制以及导致外周严重副作用的药物释放动力学。与普遍看法相反，神经退行性疾病和神经系统疾病本质上可能是多系统的，这给它们的潜在治疗带来了诸多困难。总体而言，本文的目的是总结脂质体技术在神经退行性疾病治疗方面的最新研究结果和进展，并展示该技术在开发新型疗法方面的潜力以及脂质体在两种最常见的神经退行性疾病——阿尔茨海默病和帕金森病中的可能应用。
